Login to Your Account



In The Clinic NEWS
Nasdaq delisting expected

More than a year after an independent data monitoring committee (IDMC) suggested that Argos Therapeutics Inc. halt the pivotal phase III ADAPT trial of lead candidate rocapuldencel-T (roca-T, formerly AGS-003) for futility, the Durham, N.C.-based company threw in the towel and said it was exploring a range of strategic alternatives, including a potential merger or sale of the company.

HONG KONG – China's Suzhou Alphamab Co. Ltd. has obtained the IND approval from regulators for its HER2 bispecific antibody, KN-026. The phase I trials will commence later this year.

SHANGHAI – Denovo Biopharma LLC, a cross-border biotech registered in San Diego and Hangzhou, has dosed the first patient in a phase III trial of DB-102 (enzastaurin) to treat diffuse large B-cell lymphoma (DLBCL). DB-102 is a serine/threonine kinase inhibitor of the PKC beta and AKT pathways.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: